Breast cancer in adolescents and young adults: A review with a focus on biology

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 11, Issue 9, 2013, Pages 1060-1069

  Tichy, Jill R ^a   Lim, Elgene ^b   Anders, Carey K ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; BRCA1 PROTEIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADORELIN DERIVATIVE; GOSERELIN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; OSTEOCLAST DIFFERENTIATION FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; STEM CELL FACTOR RECEPTOR; TAMOXIFEN; TRIPTORELIN; ZOLEDRONIC ACID;

ADOLESCENT; ADULT; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SCREENING; CANCER STAGING; CELL SUBPOPULATION; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL; CRYOPRESERVATION; DISEASE FREE SURVIVAL; DRUG CHOICE; EMBRYO TRANSFER; FAMILIAL CANCER; FAMILY PLANNING; FEMALE INFERTILITY; FERTILIZATION IN VITRO; GENETIC COUNSELING; GENOME ANALYSIS; GROUPS BY AGE; HUMAN; HUMAN RELATION; INFERTILITY THERAPY; LYMPH VESSEL METASTASIS; MASTECTOMY; MULTIPLE CYCLE TREATMENT; OOCYTE MATURATION; OVARY; OVERALL SURVIVAL; PATIENT DECISION MAKING; PERSONALIZED MEDICINE; PHENOTYPE; POSTMENOPAUSE; PREMENOPAUSE; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RECURRENCE FREE SURVIVAL; TISSUE PRESERVATION; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE;

ADOLESCENT; AGE FACTORS; BREAST NEOPLASMS; FEMALE; HUMANS; PREGNANCY; QUALITY OF LIFE; YOUNG ADULT;

EID: 84885100775     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2013.0128     Document Type: Article

References (58)

1. Closing the gap: research and cancer care imperatives for adolescents and young adults with cancer; report of the Adolescent and Young Adult Oncology Progress Review Group. Available at: http://planning.cancer.gov/library/AYAO- PRG-Report-2006- FINAL.pdf. Accessed July 30, 2013.
2. National Cancer Institute. A Snapshot of Adolescent and Young Adult Cancers. Available at: http://www.cancer.gov/ researchandfunding/snapshots/ adolescent-young-Adult. Accessed July 30, 2013.
3. Bleyer A, Barr R, Hayes-Lattin B, et al. The distinctive biology of cancer in adolescents and young adults. Nat Rev Cancer 2008;8:288-298. (Pubitemid 351430865)
4. Gabriel CA, Domchek SM. Breast cancer in young women. Breast Cancer Res 2010;12:212.
5. Gnerlich JL, Deshpande AD, Jeffe DB, et al. Elevated breast cancer mortality in young women (
6. Coombs NJ, Cronin KA, Taylor RJ, et al. The impact of changes in hormone therapy on breast cancer incidence in the US population. Cancer Causes Control 2010;21:83-90.
7. Anders CK, Johnson R, Litton J, et al. Breast cancer before age 40 years. Semin Oncol 2009;36:237-249.
8. Go RS, Gundrum JD. Cancer in the adolescent and young adult (AYA) population in the United States: current statistics and projections [abstract]. J Clin Oncol 2011;29(Suppl):Abstract 6072.
9. Ferlay J, Shin H, Bray F, et al. GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. Lyon, France: International Agency for Research on Cancer; 2010. Available at: http://globocan.iarc.fr. Accessed July 30, 2013.
10. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010;19:1893-1907.
11. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006;24:2137-2150. (Pubitemid 46655601)
12. Adami HO, Malker B, Holmberg L, et al. The relation between survival and age at diagnosis in breast cancer. N Engl J Med 1986;315:559.
13. Holli K, Isola J. Effect of age on the survival of breast cancer patients. Eur J Cancer 1997;33:425-428. (Pubitemid 27168069)
14. El Saghir NS, Seoud M, Khalil MK, et al. Effects of young age at presentation on survival in breast cancer. BMC Cancer 2006;6:194.
15. Nixon AJ, Neuberg D, Hayes DF, et al. Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. J Clin Oncol 1994;12:888-894. (Pubitemid 24145313)
16. Kollias J, Elston C, Ellis I, et al. Early-onset breast cancer- histopathological and prognostic considerations. Br J Cancer 1997;75:1318-1323. (Pubitemid 27179822)
17. Johnson RH, Chien FL, Bleyer A. Incidence of breast cancer with distant involvement among women in the United States, 1976 to 2009. JAMA 2013;309:800-805.
18. Colleoni M, Rotmensz N, Robertson C, et al. Very young women ( (Pubitemid 34704980)
19. Anders CK, Hsu DS, Broadwater G, et al. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 2008;26:3324-3330.
20. Azim HA Jr, Michiels S, Bedard PL, et al. Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. Clin Cancer Res 2012;18:1341-1351.
21. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-752.
22. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003;100:8418-8423. (Pubitemid 36842560)
23. The Cancer Genome Atlas Network. The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
24. Anders CK, Fan C, Parker JS, et al. Breast carcinomas arising at a young age: unique biology or a surrogate for aggressive intrinsic subtypes? J Clin Oncol 2011;29:e18-20.
25. Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009;27:1160-1167.
26. Lim E, Vaillant F, Wu D, et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 2009;15:907-913.
27. Goodwin PJ. Management of familial breast cancer risk. Breast Cancer Res Treat 2000;62:19-33. (Pubitemid 30609561)
28. Brose MS, Rebbeck TR, Calzone KA, et al. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 2002;94:1365-1372. (Pubitemid 35154141)
29. Malone KE, Daling JR, Neal C, et al. Frequency of BRCA1/ BRCA2 mutations in a population-based sample of young breast carcinoma cases. Cancer 2000;88:1393-1402. (Pubitemid 30155177)
30. Atchley DP, Albarracin CT, Lopez A, et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 2008;26:4282-4288.
31. Gonzalez-Angulo AM, Timms KM, Liu S, et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 2011;17:1082-1089.
32. Bane AL, Beck JC, Bleiweiss I, et al. BRCA2 mutation-Associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays. Am J Surg Pathol 2007;31:121-128. (Pubitemid 46036911)
33. Carey LA. American Society of Clinical Oncology: Self-Evaluation Program: Breast Cancer. ASCO Self Evaluation Program (ASCO-SEP): Alexandria, VA: American Society of Clinical Oncology; 2010:113.
34. Kleihues P, Schäuble B, Zur Hausen A, et al. Tumors associated with p53 germline mutations: a synopsis of 91 families. Am J Pathol 1997;150:1-13. (Pubitemid 27027090)
35. Masciari S, Dillon DA, Rath M, et al. Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort. Breast Cancer Res Treat 2012;133:1125-1130.
36. Melhem?Bertrandt A, Bojadzieva J, Ready KJ, et al. Early onset HER2?positive breast cancer is associated with germline TP53 mutations. Cancer 2012;118:908-913.
37. Wilson JRF, Bateman AC, Hanson H, et al. A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations. J Med Genet 2010;47:771-774.
38. Langerod A, Zhao H, Borgan O, et al. TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast Cancer Res 2007;9:R30.
39. Eng C. PTEN Hamartoma Tumor Syndrome (PHTS). Available at: http://www.ncbi.nlm.nih.gov/books/NBK1488/. Accessed July 30, 2013.
40. Daly MB, Axilbund JE, Buys SS, et al. NCCN Clinical Practice Guidelines in Oncology for Genetic/Familial High-Risk Assessment: Breast and Ovarian. Version 3, 2013. Available at: NCCN.org. Accessed July 30, 2013.
41. Tai YC, Domchek S, Parmigiani G, Chen S. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2007;99:1811-1814. (Pubitemid 351767200)
42. Swerdlow AJ, Schoemaker MJ, Higgins CD, et al. Cancer incidence and mortality in men with Klinefelter syndrome: a cohort study. J Natl Cancer Inst 2005;97:1204-1210. (Pubitemid 41258226)
43. Theriault RL, Carlson RW, Allred C, et al. NCCN Clinical Practice Guidelines in Oncology for Breast Cancer. Version 3, 2013. Available at: NCCN.org. Accessed July 30, 2013.
44. Ovarian ablation in early breast cancer: overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1996;348:1189-1196.
45. Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009;360:679-691.
46. Roché H, Kerbrat P, Bonneterre J, et al. Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial. Ann Oncol 2006;17:1221-1227. (Pubitemid 44288212)
47. Klijn J, Blamey R, Boccardo F, et al. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-Analysis of four randomized trials. J Clin Oncol 2001;19:343-353. (Pubitemid 32112845)
48. Cuzick J, Ambroisine L, Davidson N, et al. Use of luteinising-hormone- releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-Analysis of individual patient data from randomised adjuvant trials. Lancet 2007;369:1711-1723.
49. Carlson RW, Theriault R, Schurman CM, et al. Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor- positive, metastatic carcinoma of the breast in premenopausal women. J Clin Oncol 2010;28:3917-3921.
50. Loible S, Jackisch C, Gade S, et al. Neoadjuvant chemotherapy in the very young 35 years of age or younger. Cancer Res 2012;72(Suppl 24):33s.
51. Lee SJ, Schover LR, Partridge AH, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006;24:2917-2931. (Pubitemid 46655598)
52. Ganz PA, Guadagnoli E, Landrum MB, et al. Breast cancer in older women: quality of life and psychosocial adjustment in the 15 months after diagnosis. J Clin Oncol 2003;21:4027-4033. (Pubitemid 46606218)
53. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996;14:1718-1729. (Pubitemid 26134232)
54. Ganz PA, Desmond KA, Leedham B, et al. Quality of life in long-term, disease-free survivors of breast cancer: a follow-up study. J Natl Cancer Inst 2002;94:39-49. (Pubitemid 34082842)
55. Partridge AH, Gelber S, Peppercorn J, et al. Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol 2004;22:4174-4183. (Pubitemid 41185188)
56. The Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology. Mature oocyte preservation: a guideline. Fertil Steril 2013;99:37-43.
57. Del Mastro L, Boni L, Michelotti A, et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer. JAMA 2011;306:269-276.
58. Munster PN, Moore AP, Ismail-Khan R, et al. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo) adjuvant chemotherapy for breast cancer. J Clin Oncol 2012;30:533-538.